Extracellular Vesicles for Tuberculosis Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberculosis (TB) are inadequate in effectively inducing a strong immune response against Mycobacterium tuberculosis, leading to slow decline in new cases and high mortality rates, highlighting the need for novel therapeutic approaches.
Innovation Solution
Administration of extracellular vesicles (EVs) engineered to express Interleukin-12 (IL-12) and TB antigens, such as ESAT6 and TB10.4, to induce a robust cellular and humoral immune response, with IL-12 linked to scaffold moieties on the surface or within the EVs to enhance immune activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional drug delivery methods (peptide immunization, DNA vaccines) are used, then treatment simplicity is maintained, but immune response effectiveness is insufficient
Solution Approach 1:
The patent uses extracellular vesicles (EVs) as intermediary carriers to deliver IL-12 and TB antigens to the immune system. These EVs act as mediators that naturally facilitate immune recognition and response, combining the simplicity of biological delivery with enhanced immunogenicity. The EVs protect the therapeutic agents while enabling effective delivery to target cells.
Solution Approach 2:
The invention creates a composite therapeutic system by loading EVs with both IL-12 cytokine and TB-specific antigens (ESAT-6, TB10.4). This composite approach within a single delivery vehicle synergistically combines multiple immunomodulatory functions, achieving robust immune response while maintaining a unified delivery platform.
2Reliability
If free-form IL-12 is administered, then delivery simplicity is maintained, but immune response induction is weak
Solution Approach 1:
EVs serve as natural intermediaries that carry IL-12 to immune cells, leveraging the vesicles' inherent ability to interact with immune system components. This intermediary approach enhances IL-12 delivery efficiency and immune cell uptake without requiring complex synthetic delivery systems.
Solution Approach 2:
The patent modifies the delivery parameters by changing IL-12 from free-form to EV-associated form. This parameter change in delivery state significantly enhances immune response induction, as EV-associated IL-12 is protected from degradation and targeted to appropriate immune cells with higher efficiency.
3Productivity
If current TB treatments are used, then treatment accessibility is maintained, but disease elimination progress is too slow
Solution Approach 1:
The EV-based vaccine induces preliminary immune memory and protection before TB infection occurs or at early stages. By pre-priming the immune system with TB antigens and IL-12 delivered via EVs, the body is prepared to mount a faster and stronger response upon exposure to actual TB bacteria, accelerating disease control.
Solution Approach 2:
The invention changes the therapeutic parameter from conventional antibiotics to an immunomodulatory approach using EV-delivered IL-12 and antigens. This parameter change targets the immune response mechanism directly, potentially achieving faster and more durable protection against TB, thereby increasing the disease elimination rate.
Data Source
AI summary
The present disclosure relates to extracellular vesicles, e.g., exosomes, comprising a cytokine, e.g., Interleukin-12 (IL-12), and, optionally, a TB antigen. Also provided herein are methods of inducing an immune response against Mycobacterium tuberculosis in a subject in need thereof comprising administering an extracellular vesicle comprising a cytokine, e.g., IL-12, and, optionally, a TB antigen.